I see an H&S formationLooking at the chart and volumes of NYSE:NVO , I guess that we have a high probability of an H&S pattern formation. Waiting for a confirmation or an invalidation
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.09 USD
12.14 B USD
33.70 B USD
3.34 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Founded
1931
FIGI
BBG000BQBKR3
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Revising the head and shoulders pattern on NOVOSince my previous analysis on Novo Nordisk OMXCOP:NOVO_B , the price has nearly reached the original target of 700.
However, I have made slight adjustments to the head and shoulders pattern, which has consequently led to a revised target at the value area low of the range from late 2023 at a
Novo Nordis Short
Shorting Novo Nordisk may be considered due to potential overvaluation, rising competition in diabetes and obesity markets, supply chain challenges, and risks from patent expirations. Regulatory hurdles, slower demand in key regions, and macroeconomic factors like healthcare budgets and inflation c
NOVO NORDISKBearish trend with a Shoulder-Head-Shoulder pattern with price target around 630DK. However, could fall a bit more if it tests support around 620DK.
Novo Nordisk Correction: Key Levels & Opportunities for InvestorNovo Nordisk, Europe’s largest publicly traded company, has experienced exceptional growth, especially in the diabetes and obesity treatment markets. Known globally for its expertise in insulin production, Novo Nordisk has also recently expanded into the obesity treatment market with products like W
NVO eyes on $111: Possible bottom and long entry with tight SL NVO has been retracing from its record highs.
Now at a fib confluence that may end the retrace.
Look for a clean bounce here for possible bottom.
$ 111.17 - 111.50 is the exact support of interest.
$ 108.35 - 108.58 is next support and for SL shield.
$ 115.73 - 111.50 to break for bottom confirmati
Novo Nordisk (NVO): Beautiful Reversal Pattern is emerging Novo Nordisk price has charted a famous and beautiful reversal pattern - Head & Shoulders.
We have 3 peaks with the middle one the tallest also called Head.
The Right Shoulder inclines down so the magnitude of the bearish move is strong.
The dotted line between valleys of the Head is called a Neckli
NVO from $115.75 to $135MODs have suggested that I provide more detail about the picks I make.
Sorry. I'm not as verbose as y'all, and I don't like things to be complicated.
My trading plan is very simple.
I buy or sell at top & bottom of parallel channels.
I confirm when price hits Fibonacci levels.
Bonus if a TTM Sq
NVO broke structureI did end up cutting my losses on my NVO trade, I was not quick enough to sell the relief rally. This chart confirms the breakdown of the stock finally after all this time. I zoomed out and drew an optimistic demand zone on the monthly chart. I expect some consolidation around the 200 EMA at this po
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NVO is featured.
